These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

445 related articles for article (PubMed ID: 26169970)

  • 1. Phase I Dose-Escalation Study of the Multikinase Inhibitor Lenvatinib in Patients with Advanced Solid Tumors and in an Expanded Cohort of Patients with Melanoma.
    Hong DS; Kurzrock R; Wheler JJ; Naing A; Falchook GS; Fu S; Kim KB; Davies MA; Nguyen LM; George GC; Xu L; Shumaker R; Ren M; Mink J; Bedell C; Andresen C; Sachdev P; O'Brien JP; Nemunaitis J
    Clin Cancer Res; 2015 Nov; 21(21):4801-10. PubMed ID: 26169970
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase 1b study of lenvatinib (E7080) in combination with temozolomide for treatment of advanced melanoma.
    Hong DS; Kurzrock R; Falchook GS; Andresen C; Kwak J; Ren M; Xu L; George GC; Kim KB; Nguyen LM; O'Brien JP; Nemunaitis J
    Oncotarget; 2015 Dec; 6(40):43127-34. PubMed ID: 26503473
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Phase I dose-escalation study of chiauranib, a novel angiogenic, mitotic, and chronic inflammation inhibitor, in patients with advanced solid tumors.
    Sun Y; Yang L; Hao X; Liu Y; Zhang J; Ning Z; Shi Y
    J Hematol Oncol; 2019 Jan; 12(1):9. PubMed ID: 30642372
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Biologic and clinical activity of tivozanib (AV-951, KRN-951), a selective inhibitor of VEGF receptor-1, -2, and -3 tyrosine kinases, in a 4-week-on, 2-week-off schedule in patients with advanced solid tumors.
    Eskens FA; de Jonge MJ; Bhargava P; Isoe T; Cotreau MM; Esteves B; Hayashi K; Burger H; Thomeer M; van Doorn L; Verweij J
    Clin Cancer Res; 2011 Nov; 17(22):7156-63. PubMed ID: 21976547
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.
    Koyama N; Saito K; Nishioka Y; Yusa W; Yamamoto N; Yamada Y; Nokihara H; Koizumi F; Nishio K; Tamura T
    BMC Cancer; 2014 Jul; 14():530. PubMed ID: 25047123
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase 2 study of lenvatinib in patients with advanced hepatocellular carcinoma.
    Ikeda K; Kudo M; Kawazoe S; Osaki Y; Ikeda M; Okusaka T; Tamai T; Suzuki T; Hisai T; Hayato S; Okita K; Kumada H
    J Gastroenterol; 2017 Apr; 52(4):512-519. PubMed ID: 27704266
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Model-based treatment optimization of a novel VEGFR inhibitor.
    Keizer RJ; Gupta A; Shumaker R; Beijnen JH; Schellens JH; Huitema AD
    Br J Clin Pharmacol; 2012 Aug; 74(2):315-26. PubMed ID: 22295876
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Safety and Pharmacokinetics of Lenvatinib in Patients with Advanced Hepatocellular Carcinoma.
    Ikeda M; Okusaka T; Mitsunaga S; Ueno H; Tamai T; Suzuki T; Hayato S; Kadowaki T; Okita K; Kumada H
    Clin Cancer Res; 2016 Mar; 22(6):1385-94. PubMed ID: 26500236
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic
    Delord JP; Robert C; Nyakas M; McArthur GA; Kudchakar R; Mahipal A; Yamada Y; Sullivan R; Arance A; Kefford RF; Carlino MS; Hidalgo M; Gomez-Roca C; Michel D; Seroutou A; Aslanis V; Caponigro G; Stuart DD; Moutouh-de Parseval L; Demuth T; Dummer R
    Clin Cancer Res; 2017 Sep; 23(18):5339-5348. PubMed ID: 28611198
    [No Abstract]   [Full Text] [Related]  

  • 10. Phase I dose-escalation study and biomarker analysis of E7080 in patients with advanced solid tumors.
    Yamada K; Yamamoto N; Yamada Y; Nokihara H; Fujiwara Y; Hirata T; Koizumi F; Nishio K; Koyama N; Tamura T
    Clin Cancer Res; 2011 Apr; 17(8):2528-37. PubMed ID: 21372218
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers.
    Adjei AA; Cohen RB; Franklin W; Morris C; Wilson D; Molina JR; Hanson LJ; Gore L; Chow L; Leong S; Maloney L; Gordon G; Simmons H; Marlow A; Litwiler K; Brown S; Poch G; Kane K; Haney J; Eckhardt SG
    J Clin Oncol; 2008 May; 26(13):2139-46. PubMed ID: 18390968
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phase IB/II Trial of Lenvatinib Plus Pembrolizumab in Patients With Advanced Renal Cell Carcinoma, Endometrial Cancer, and Other Selected Advanced Solid Tumors.
    Taylor MH; Lee CH; Makker V; Rasco D; Dutcus CE; Wu J; Stepan DE; Shumaker RC; Motzer RJ
    J Clin Oncol; 2020 Apr; 38(11):1154-1163. PubMed ID: 31961766
    [TBL] [Abstract][Full Text] [Related]  

  • 13. First-in-human, phase I dose-escalation study of the safety, pharmacokinetics, and pharmacodynamics of RO5126766, a first-in-class dual MEK/RAF inhibitor in patients with solid tumors.
    Martinez-Garcia M; Banerji U; Albanell J; Bahleda R; Dolly S; Kraeber-Bodéré F; Rojo F; Routier E; Guarin E; Xu ZX; Rueger R; Tessier JJ; Shochat E; Blotner S; Naegelen VM; Soria JC
    Clin Cancer Res; 2012 Sep; 18(17):4806-19. PubMed ID: 22761467
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Phase I dose escalation study of telatinib, a tyrosine kinase inhibitor of vascular endothelial growth factor receptor 2 and 3, platelet-derived growth factor receptor beta, and c-Kit, in patients with advanced or metastatic solid tumors.
    Eskens FA; Steeghs N; Verweij J; Bloem JL; Christensen O; van Doorn L; Ouwerkerk J; de Jonge MJ; Nortier JW; Kraetzschmar J; Rajagopalan P; Gelderblom H
    J Clin Oncol; 2009 Sep; 27(25):4169-76. PubMed ID: 19636022
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Lenvatinib: Role in thyroid cancer and other solid tumors.
    Cabanillas ME; Habra MA
    Cancer Treat Rev; 2016 Jan; 42():47-55. PubMed ID: 26678514
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Second-line lenvatinib in patients with recurrent endometrial cancer.
    Vergote I; Powell MA; Teneriello MG; Miller DS; Garcia AA; Mikheeva ON; Bidzinski M; Cebotaru CL; Dutcus CE; Ren M; Kadowaki T; Funahashi Y; Penson RT
    Gynecol Oncol; 2020 Mar; 156(3):575-582. PubMed ID: 31955859
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Safety and tolerability of quizartinib, a FLT3 inhibitor, in advanced solid tumors: a phase 1 dose-escalation trial.
    Papadopoulos KP; Ben-Ami E; Patnaik A; Trone D; Li J; Demetri GD
    BMC Cancer; 2018 Aug; 18(1):790. PubMed ID: 30081867
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Dose Finding of Lenvatinib in Subjects With Advanced Hepatocellular Carcinoma Based on Population Pharmacokinetic and Exposure-Response Analyses.
    Tamai T; Hayato S; Hojo S; Suzuki T; Okusaka T; Ikeda K; Kumada H
    J Clin Pharmacol; 2017 Sep; 57(9):1138-1147. PubMed ID: 28561918
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Treatment-emergent hypertension and efficacy in the phase 3 Study of (E7080) lenvatinib in differentiated cancer of the thyroid (SELECT).
    Wirth LJ; Tahara M; Robinson B; Francis S; Brose MS; Habra MA; Newbold K; Kiyota N; Dutcus CE; Mathias E; Guo M; Sherman SI; Schlumberger M
    Cancer; 2018 Jun; 124(11):2365-2372. PubMed ID: 29656442
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A phase I study with neratinib (HKI-272), an irreversible pan ErbB receptor tyrosine kinase inhibitor, in patients with solid tumors.
    Wong KK; Fracasso PM; Bukowski RM; Lynch TJ; Munster PN; Shapiro GI; Jänne PA; Eder JP; Naughton MJ; Ellis MJ; Jones SF; Mekhail T; Zacharchuk C; Vermette J; Abbas R; Quinn S; Powell C; Burris HA
    Clin Cancer Res; 2009 Apr; 15(7):2552-8. PubMed ID: 19318484
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 23.